Take­da clears fi­nal reg­u­la­to­ry hur­dle to com­plet­ing its $62B Shire deal. Now on­ly one ob­sta­cle re­mains

Take­da has just put the last reg­u­la­to­ry piece in place for its $62 bil­lion takeover of Shire. The Eu­ro­pean Com­mis­sion has pro­vid­ed its bless­ing for the deal, with one re­quire­ment. 

As ex­pect­ed, Take­da will have to di­vest SHP647 so it can re­tain its block­buster drug En­tyvio, where the Eu­ro­peans saw an over­lap. The oth­er reg­u­la­tors in­volved in the US and Japan have al­ready signed off.

Now there’s just one last ob­sta­cle to clear as CEO Christophe We­ber looks to vault past a group of dis­si­dent Japan­ese share­hold­ers and com­plete the jour­ney in­to the top ranks of in­dus­try play­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER